Author(s)

Théodora Mahoukèdè Zohoncon^1,2,3*, Denise P. Ilboudo^3,4,5, Lionel Dahourou², Titeon Rose Clémence Ido Da¹, Luc Zongo^1,3,6, Jacques Simpore^1,2,3,5

¹Laboratoire de Biologie Moléculaire, Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, Burkina Faso.
²Faculté des Sciences de la Santé (FSDS), Université Saint Thomas d’Aquin (USTA), Ouagadougou, Burkina Faso.
³Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
⁴Institut Supérieur du Développement Durable (ISDD), Université de Fada N’Gourma, Fada N’Gourma, Burkina Faso.
⁵Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), UFR/SVT, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
⁶Unité de Formation et de Recherche en Sciences de la Santé (UFR/SDS), Université Saint Dominique d’Afrique de l’Ouest, Kombissiri, Burkina Faso.

The present study aims to describe the clinical and paraclinical profile of patients infected by viral hepatitis B and C and follow-up. The clinical and paraclinical data used in this description are from patients infected by viral hepatitis B and C of the HOSCO Hepato-Gastroenterological Department from May 15, 2021 to July 23, 2021. The informed consent was provided to each patient included in this study. “Univariate analyses were evaluated using Pearson’s Chi2 test” using R software version 4.0.2. During the study period, we identified 149 patients with viral hepatitis B and/or C who met our inclusion criteria. The sex ratio was 0.83 at the rate of 68 men for 81 women with the average age at 37.17 years ± 12.21 years. The most represented age group was 30 - 44 years (49.7%). The most incriminated risk factors were medical care by injection (62.58%), excision (31.90%), blood transfusion (4.29%) and scarification (1.23%). HBV infection was the majority with a frequency of 95.97%. The HBV viral load was measured in 91.95% of patients, 77.18% of whom had a detectable DNA viral load ≤ 2000 IU/mL. The clinical and biological course was good in patients after therapeutic initiation. HBV-HCV-HIV co-infection was 0.67%. Abdominal ultrasound was normal in 87.92% of patients. Fibrosis was minimal and moderate in 58.39% and 19.46% of patients. Among patients, 52.35% were on Tenofovir therapy, 2.68% on Sofosbuvir/Velpatasvir, 0.67% on ARVs and 44.29% did not require treatment. Viral hepatitis B and C are common, and both affect sex. Thus, new screening strategies need to be implemented to improve the diagnosis of hepatitis B and C. Effective strategies against viral hepatitis B and C must be developed, subsequently.

Hepatitis B and C, Co-Infection, Primary Liver Cancer (PLC), Cirrhosis, HOSCO

Zohoncon, T. , Ilboudo, D. , Dahourou, L. , Da, T. , Zongo, L. and Simpore, J. (2023) Clinical and Paraclinical Profiling of Patients with Viral Hepatitis B and C Attending Saint Camille Hospital in Ouagadougou (HOSCO). Journal of Biosciences and Medicines, 11, 225-240. doi: 10.4236/jbm.2023.1110021.